| Literature DB >> 28454485 |
Mahdi Alikhani Pour1, Soroush Sardari1, Ali Eslamifar2, Abid Azhar3, Mohammad Rezvani4, Milad Nazari2.
Abstract
Backgroung: Medicinal plants, as a complementary medicine, have been used to treat various diseases since ancient times. These plants have numerous beneficial applications and are the source of certain conventional drugs. In diseases such as stroke and ischemia, which are caused by several factors, abnormal coagulation is an important causative factor. Accordingly, novel and effective therapies such as herbal remedies should be practiced to prevent such lethal diseases.Entities:
Keywords: Cheminformatics; Cardiovascular diseases; Medicinal plants
Year: 2017 PMID: 28454485 PMCID: PMC5572436 DOI: 10.18869/acadpub.ibj.21.6.400
Source DB: PubMed Journal: Iran Biomed J ISSN: 1028-852X
The 15 selected medicinal plants with the help of cheminformatics approaches
| No. | Voucher specimen | Plant | Used part of the plant | Place of cultivation | Major chemical compounds (%) |
|---|---|---|---|---|---|
| 1 | P148-16 | Flower and leaves | Varamin, Iran | Acacetin (16), Diosmetin (10), salvigenin (6)[ | |
| 2 | P148-17 | Seed | Isfahan, Iran | Rutin (28.5), Apigenin(10.5), Luteolin (9), Vanillic acid (0.36), Ellagic acid (0.57)[ | |
| 3 | P148-18 | Dried bud | Mahalat, Iran | Hexadecanoic acid (28.7), Benzyl benzoate (12.6), Eugenol (18.22)[ | |
| 4 | P148-19 | Seed | India | Terpenyl acetate (64.5), Cineole (11.8), Terpineol (5.51), Limonene (2.23)[ | |
| 5 | P148-20 | Seed | Ardabil, Iran | N/A | |
| 6 | P148-21 | Flower and leaves | Mazandaran, Iran | Eudesmol (11.93), Germacrene (9.37), Citronellyl formate (9.50), Citronellol (9.90)[ | |
| 7 | P148-22 | Flower and leaves | Isfahan, Iran | N/A | |
| 8 | P148-23 | Fruit | Indonesia | Tannins (40%: Gallic acid, Sitosterol, Ellagic acid)[ | |
| 9 | P148-24 | Resin | India | Arabinogalactan, diferulic acid[ | |
| 10 | P148-25 | Resin | Shiraz, Iran | N/A | |
| 11 | P148-26 | Flower | Ardabil, Iran | Piperitone (35.2), Elemol (14.1), β-Eudesmol (6.9), Spathulenol (5), Caryophyllene oxide (4.0), Hexadecanoic acid (4)[ | |
| 12 | P148-27 | Flower and leaves | Yazd, Iran | Caryophyllene (14.4), Spathulenol (11.6), Germacrene (8.1), α-Caryophyllene (2.7)[ | |
| 13 | P148-28 | Resin | Shiraz, Iran | 2-Hexenal (20.7), Hexanol (5.8), Octanol (8.1), Geraniol (10.4)[ | |
| 14 | P148-29 | Seed | Isfahan, Iran | Sabinene (50.31), Elemol (5.74), Limonene (7.50), Terpinene (3.62), α-Pinene (7.97), β-Pinene (3.71), Terpinen-4-ol (3.79)[ | |
| 15 | P148-30 | Seed | Tehran, Iran | Chlorogenic acid, Caffeic acid, Nasunin[ |
N/A, not available (according to literature review)
Fig. 1The effect of 15 selected medicinal plants on prothrombin time (A) and activated partial thromboplastin time (B) analyzed by one way analysis of variance (ANOVA) and Dunnett’s post-test. Samples: DMSO (Control), Dracocephalum moldavica (1), Vachellia nilotica (2), Dianthus caryophyllus (3), Elettaria cardamomum (4), Zea mays (5), Marrubium vulgare (6), Rumex acetosella (7), Terminalia bellirica (8), Acacia senegal (9), Astragalus arbusculinus (10), Centaurea depressa (11), Origanum vulgare (10 µg/ml; 12A), Origanum vulgare (100 µg/ml; 12B), Styrax officinalis (13), Juniperus sabina (14), Solanum melongena (15), Glycyrrhiza glabra (PCA) in concentration of 100 µg per ml, and heparin in concentrations of 0.01 IU (PCB1) and 0.1 IU (PCB2). *P<0.05, **P<0.01, and *** P<0.001 as compared to the control (standard t-test; means±standard deviation; n=3).
Results of in vitro coagulation test
| Sample[ | Dose (µg/ml) | APTT (Seconds) | PT (Seconds) |
|---|---|---|---|
| Control | DMSO | 75.30±0.57 | 17.66±1.53 |
| 100 | 76.00±1.00 | 17.66±1.15 | |
| 100 | 74.60±0.57 | 17.50±1.32 | |
| 100 | 76.16±0.76 | 17.60±0.57 | |
| 100 | 73.83±0.76 | 17.30±0.57 | |
| 100 | 75.00±1.00 | 16.66±0.28 | |
| 100 | 75.00±0.50 | 18.50±0.50 | |
| 100 | 76.16±1.04 | 18.00±1.32 | |
| 100 | 86.83±1.25 | 18.00±1.00 | |
| 100 | 74.60±0.57 | 17.83±1.04 | |
| 100 | 94.60±1.52 | 17.83±0.28 | |
| 100 | 76.50±0.50 | 18.16±0.76 | |
| 10 | 85.30±0.57 | 17.33±0.57 | |
| 100 | 91.50±1.50 | 18.16±0.76 | |
| 100 | 75.30±0.57 | 17.16±0.76 | |
| 100 | 76.16±0.76 | 17.66±0.57 | |
| 100 | 75.83±1.04 | 16.83±0.28 | |
| 100 | 82.66±1.53 | 17.30±0.57 | |
| Heparin[ | 0.01 IU | 152.66±2.51 | 15.50±0.50 |
| Heparin[ | 0.1 IU | 204.00±2.64 | 17.33±0.57 |
| Heparin[ | 1 IU | NC[ | NC[ |
Each value represents the means±standard deviation (n=3).
Positive control;
No clotting;
P<0.05,
P<0.01, and
P<0.001 as compared to the control (standard t-test).